Status: Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Participants needed: 614
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Canadian Cancer Trials GroupUpdated: Jun 9, 2026Locations: 30
Eligibility criteria
Histologically confirmed melanoma that is unresectable / metastatic (stage III o... [+9]
Patients not willing to stop anti-PD-1 therapy, if randomized to the intermitten... [+1]